Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Gains from Sales and Divestitures (2023 - 2025)

BioXcel Therapeutics (BTAI) has 3 years of Gains from Sales and Divestitures data on record, last reported at $21000.0 in Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures fell 69.57% year-over-year to $21000.0; the TTM value through Sep 2025 reached $21000.0, down 69.57%, while the annual FY2023 figure was $67000.0, N/A changed from the prior year.
  • Gains from Sales and Divestitures reached $21000.0 in Q3 2025 per BTAI's latest filing, up from $2.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $69000.0 in Q3 2024 and bottomed at $2.0 in Q1 2025.
  • Average Gains from Sales and Divestitures over 3 years is $42571.7, with a median of $55000.0 recorded in 2023.
  • Peak YoY movement for Gains from Sales and Divestitures: grew 13.11% in 2024, then tumbled 69.57% in 2025.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $67000.0 in 2023, then rose by 2.99% to $69000.0 in 2024, then crashed by 69.57% to $21000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $21000.0 in Q3 2025, $2.0 in Q1 2025, and $69000.0 in Q3 2024.